newsfilter
← Latest News
GlobeNewswire·

Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update

RAP-219 Phase 2a trial in patients with refractory focal epilepsy remains on track with topline results expected in the third quarter of 2025RAP-219 Phase 2a trial in patients with bipolar mania remains on track to